Skip to content

19 October 2026 · Antiksha Joshi · 4 min read

Drug Development to Commercialisation: Every stage needs to think “Operational Excellence.”

Drug Development to Commercialisation: Every stage needs to think “Operational Excellence.”

In the highly regulated life sciences industry, where products and services significantly impact human life, organizations often prioritize checking compliance boxes. Drug development and lifecycle management are complex, time-consuming, and costly processes, leading many to do just enough to meet regulatory requirements. However, it’s time to shift our focus from mere compliance to operational excellence.

As global events transform business landscapes, leaders in life sciences must embrace operational excellence at every stage of drug development. This month, I explore why operational excellence has become an urgent necessity.

Current Challenges in Drug Development and Commercialization

  1. Evolving regulatory requirements
  2. Securing steady funding, especially for early development and clinical trials
  3. Ensuring consistent manufacturing operations to meet regulatory standards
  4. The need for accelerated time-to-market
  5. Skill shortages
  6. Supply chain disruptions
  7. Volatile geopolitical situations
  8. Rapid technological advancements
  9. Recurring regulatory non-compliance issues, such as Form 483 observations and warning letters

Navigating these challenges demands agility, robust change management, proactive risk handling, and efficiency. This is where operational excellence comes into play.

Debunking Myths About Operational Excellence in Life Sciences

  • Myth 1: It’s only for large organizations with less stringent regulations.
  • Myth 2: It’s just a buzzword for marketing brochures.
  • Myth 3: Implementing OE tools will divert focus from regulatory compliance.
  • Myth 4: It requires extensive resources.

But are these perceptions accurate?

Understanding Operational Excellence (OE)

Operational Excellence (OE) is the systematic application of principles and tools designed to enhance organizational performance and foster a culture of continuous improvement. The goals of OE include:

  • Driving continual improvement
  • Enhancing efficiency
  • Reducing waste (resources, time, money)
  • Maximizing customer satisfaction

OE enables organizations to achieve more with the same resources through better employee engagement and streamlined processes. It’s about optimizing available resources and tools, not just implementing high-tech solutions or cutting corners.

When viewed in this context, the value of incorporating OE principles within life sciences organizations becomes clear, regardless of the drug product lifecycle stage.

Tools for Achieving Operational Excellence

Several approaches and methodologies can help achieve operational excellence. Here are some tools organizations can use to design, implement, and improve their processes:

  • Lean Six Sigma
  • Kaizen
  • Total Quality Management (TQM)
  • Just-In-Time (JIT) manufacturing
  • 5S methodology

While these tools are widely used in other industries, life sciences organizations can build on existing elements of their compliance and Quality Management System (QMS) programs. Here are a few examples:

1. Process Mapping:

A CRO maps out the entire process of clinical trial management, from protocol development to regulatory submission. The map visually represents each step, including stakeholders such as clinical research associates, data managers, and regulatory affairs specialists. Through this exercise, the company identifies a bottleneck in the data collection phase, where delays often occur due to manual data entry. By recognizing this gap, the company can implement automated data capture systems, reducing delays and improving data accuracy.

2. Standard Operating Procedures (SOPs):

A manufacturing department trains its staff on how to write effective SOPs. Initially, the SOPs were lengthy and complex, leading to frequent errors and non-compliance issues. By involving employees in process mapping exercises, the department identifies unnecessary steps and simplifies the language. The revised SOPs are clearer and more concise, leading to fewer errors and improved compliance during production.

3. Risk Management:

A pharmaceutical company extends its risk-based approach to project management for a new drug launch. Instead of focusing solely on product quality risks, the company assesses risks related to supply chain disruptions, regulatory changes, and market dynamics. By identifying these potential risks early, the company develops contingency plans, such as securing alternative suppliers and preparing for regulatory submissions in multiple regions. This proactive approach ensures a smoother launch and minimizes delays.

4. Internal Audits:

An internal audit team creates an audit plan focused on recurring issues in the quality control laboratory. Instead of conducting routine audits, the team targets areas with frequent deviations, such as sample handling and data integrity. The findings from these audits are used to train laboratory staff on best practices and identify systemic issues, such as outdated equipment or inadequate training. The company then prioritizes improvements in these areas, leading to a reduction in deviations and improved overall quality.

5. Management Review:

During a quarterly management review, a pharmaceutical company examines trends in customer complaints and adverse event reports. Instead of focusing solely on compliance with regulatory requirements, the management team looks for patterns and potential non-compliances. They identify a trend of complaints related to packaging issues and decide to invest in improved packaging materials and processes. This proactive approach addresses customer concerns and enhances product quality, leading to increased customer satisfaction and reduced regulatory risks.

Conclusion

Operational Excellence is more than a strategy or buzzword; it’s a mindset that permeates every facet of an organization. By integrating OE methodologies, life sciences companies can unlock their full potential, driving efficiency, innovation, and sustainable compliance. In an era demanding more agile and reliable drug development, operational excellence is the cornerstone of success.

And organizations don’t need to invest large resources immediately- small changes in using existing quality system tools can be a great starting point.

More insights

Inspection Readiness Starts with People: Reinventing Staff Training

Inspection Readiness Starts with People: Reinventing Staff Training

19 October 2026

Inspection Readiness in 2026: From Compliance Checklists to Systemic Integrity

Inspection Readiness in 2026: From Compliance Checklists to Systemic Integrity

19 October 2026

Four Questions That Expose Hidden Data Integrity Risks

Four Questions That Expose Hidden Data Integrity Risks

19 October 2026

URMI

Stay in touch.

Find more of my writing and updates on LinkedIn.